- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03506256
Noroxin Efficacy and Safety Trial (NEST)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Urinary tract infections (UTIs) are some of the most common bacterial infections, affecting 150 million people each year worldwide. Clinically, UTIs are categorized as uncomplicated or complicated. Uncomplicated UTIs typically affect individuals who are otherwise healthy and have no structural or neurological urinary tract abnormalities; these infections are differentiated into lower UTIs (cystitis) and upper UTIs (pyelonephritis). Several risk factors are associated with cystitis, including female gender, a prior UTI, sexual activity, vaginal infection, diabetes, obesity and genetic susceptibility.
UTIs are caused by both Gram-negative and Gram-positive bacteria, as well as by certain fungi. The most common causative agent for both uncomplicated and complicated UTIs is uropathogenic Escherichia coli (UPEC). For the agents involved in uncomplicated UTIs, UPEC is followed in prevalence by Klebsiella pneumoniae, Staphylococcus saprophyticus, Enterococcus faecalis, group B Streptococcus (GBS), Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus and Candida spp. Currently, antibiotics - such as trimethoprim sulfamethoxazole, floxacin and ampicillin - are the most commonly recommended therapeutics for UTIs6. UTIs are becoming increasingly difficult to treat owing to the widespread emergence of an array of antibiotic resistance mechanisms. Of particular concern are members of the family Enterobacteriaceae, including E. coli and K. pneumoniae, which have both acquired plasmids encoding extended-spectrum β-lactamases (ESBLs). These plasmids rapidly spread resistance to third-generation cephalosporins as well as other antibiotics.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent
- At least one typical symptom of acute, lower urinary tract infection out of dysuria, frequency, macrohaematuria, cloudy or smelly urine or self-diagnosed cystitis
Exclusion Criteria:
- Duration of UTI symptoms for more than 7 days before physician's visit
- Clinical signs of invasiveness such as fever (axillary body temperature >38 degrees Celsius), costovertebral pain or tenderness, rigors, nausea or vomiting
- Known or suspicion of anatomical or functional abnormality of the urinary tract
- Vaginal symptoms: discharge, irritation
- Diabetes mellitus
- Immunosuppression (e.g. prednisone equivalent >10mg per day for >14 days, chemotherapy, radiotherapy, immunomodulators, HIV infection, neutropenia)
- Any other serious comorbidity as judged by the treating physician
- Bladder catheter in situ or during the past 30 days
- Pregnancy
- Recurrent urinary tract infection (more than 3 infections during the last 12 months)
- Antibiotic treatment during the last 4 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Norofloxacin
The recommended dosage of norfloxacin for urinary-tract infections in adults is 400 mg orally every 12 hours; the drug should be given for 7 to 10 days in uncomplicated infections and for 10 to 21 days in complicated ones.
Adverse drug effects were mild and included disturbances of the gastrointestinal tract and the central nervous system.
The study shall be completed in accordance with the ICH topic E6 (R1)(CPMP/ICH/one hundred thirty five/95) guiding principle for top medical practice and the ideas enunciated within the announcement of Helsinki and the approval by way of an Institutional Ethics Committee.
|
Norfloxacin is an oral fluoroquinolone antimicrobial agent used for the treatment of uncomplicated and complicated urinary tract infections.
The drug antagonizes DNA gyrase, an enzyme essential for bacterial DNA replication and is active in vitro against virtually all bacterial pathogens causing urinary tract8
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients treated with Noroxin (Efficacy)
Time Frame: 14 Days
|
To evaluate efficacy of Norfloxacin by measuring clinical response, the resolution of sign and symptoms of post-therapy as compared to start of therapy
|
14 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Adverse Effects with Noroxin (Safety)
Time Frame: 14 Days
|
To determine number of patients that experienced Adverse effects
|
14 Days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Urologic Diseases
- Urinary Tract Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors
- Norfloxacin
Other Study ID Numbers
- OBS-NEST-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Tract Infections
-
GlaxoSmithKlineCompletedInfections, Urinary TractEgypt
-
University of WashingtonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Iterum Therapeutics, International LimitedCompletedComplicated Urinary Tract InfectionsUnited States, Estonia, Hungary, Georgia, Latvia
-
Shandong Branden Med.Device Co.,LtdTerminatedUrinary Tract Infection | Urinary CathetersChina
-
Inmunotek S.L.CompletedUrinary Tract Infection BacterialSpain, United Kingdom
-
Newcastle-upon-Tyne Hospitals NHS TrustCambridge University Hospitals NHS Foundation Trust; University of Southampton and other collaboratorsCompletedUrinary Tract Infections, RecurrentUnited Kingdom
-
AbbottCompletedUrinary Tract Infections (UTIs)Pakistan
-
Hospital del Río HortegaCompletedUrinary Tract Infection
-
Assaf-Harofeh Medical CenterNanovibronixUnknown
-
Bergaliden BarnavårdscentralCompleted
Clinical Trials on Norfloxacin 400 MG
-
Dr. Reddy's Laboratories LimitedXenoPort, Inc.Completed
-
Postgraduate Institute of Medical Education and...Completed
-
Dr. Reddy's Laboratories LimitedCompleted
-
Daiichi Sankyo, Inc.CompletedHealthy VolunteersUnited States
-
Humanis Saglık Anonim SirketiNovagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. StiCompleted
-
Medicines for Malaria VentureAbbVieCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedAsthma; Allergic RhinitisChina
-
GlaxoSmithKlineCompletedPsoriasisGermany, United Kingdom
-
Guangdong Raynovent Biotech Co., LtdCompleted
-
CTI BioPharmaCovanceCompleted